During the recent US midterm elections, voters in California approved a ballot initiative that will direct $8.4 billion (£6.4 billion) in public funds to immunology and immunotherapy research in the state. This is the largest injection of public money for science ever approved in the country via an election. The controversial initiative, which over half of 12 million voters in California approved, could serve as a model for research universities across the country to thrive during times of fiscal constraints or political turmoil.
Half of the proceeds provided through Proposition 38 are poised to go to one University of California–affiliated nonprofit research institute that was co-founded by billionaire philanthropist Gary Michelson because it appears to be the only organisation that fits the statute’s very narrow criteria. Michelson spearheaded the effort to qualify the initiative for the 3 November ballot and reportedly contributed tens of millions of dollars in the process.
This is not the first time that California has financed scientific research in this way. In November 2004, in the wake of former president George W Bush banning federal funding for new human embryonic stem cell lines, voters in the state approved a $3 billion bond to establish the California Institute for Regenerative Medicine (CIRM) to award research grants and oversee regulatory standards in this area. This institute is still going strong.
In November 2020, California voters passed a new ballot initiative authorising another $5.5 billion in state money to continue and expand CIRM’s activities. And earlier this year, CIRM’s annual research budget of $662 million was approved. So, these methods can succeed and work long term. There is now solid infrastructure in place to ensure embryonic stem cell research can continue in California despite political headwinds.
Prop 38 came at an opportune time when federal policy shifts under the current Trump administration have created major funding and regulatory obstacles for immunology with millions of dollars in cuts to mRNA vaccine research, for example. However, there are risks. Such direct-democracy mechanisms will likely be the purview of wealthy states and political donors, as well as high visibility fields that are sexier and more health-related than chemistry (although biochemistry research might fit the bill).
The American Association of Immunologists (AAI) endorsed Prop 38 this summer, but closer to the election media reports indicated internal disagreement within some parts of the organisation concerned that it could represent a ‘windfall’ for the research centre co-founded by Michelson. After its approval, AAI told me it was ‘not able to comment any further on Prop 38’ indicating that the issue remains controversial.